Predicted Value of PD-L1 for Patients With Cervical Cancer Treated With Pembrolizumab

J Clin Oncol. 2024 May 1;42(13):1596. doi: 10.1200/JCO.23.02479. Epub 2024 Mar 7.

Authors

Peng-Hui Luo¹, Dun-Chang Mo¹, Han-Lei Wang¹, Xiu-Juan Liang¹, Jian-Feng Huang¹

Affiliation

¹ Peng-Hui Luo, MD, Dun-Chang Mo, MD, Han-Lei Wang, MD, Xiu-Juan Liang, MD, and Jian-Feng huang, MDRadiotherapy Department, The Third Affiliated Hospital of Guangxi Medical University, Nanning, China.

PMID: 38452320
DOI: 10.1200/JCO.23.02479

No abstract available

Publication types

Research Support, Non-U.S. Gov't
Letter

MeSH terms

Antibodies, Monoclonal, Humanized* / adverse effects
Antibodies, Monoclonal, Humanized* / therapeutic use
Antineoplastic Agents, Immunological / adverse effects
Antineoplastic Agents, Immunological / therapeutic use
B7-H1 Antigen* / antagonists & inhibitors
Biomarkers, Tumor
Female
Humans
Immune Checkpoint Inhibitors / adverse effects
Immune Checkpoint Inhibitors / therapeutic use
Middle Aged
Predictive Value of Tests
Uterine Cervical Neoplasms* / drug therapy
Uterine Cervical Neoplasms* / pathology

Substances

pembrolizumab
Antibodies, Monoclonal, Humanized
B7-H1 Antigen
CD274 protein, human
Antineoplastic Agents, Immunological
Immune Checkpoint Inhibitors
Biomarkers, Tumor